With the current New England Journal Article on Avandia and it’s increased risks for cardiovascular problems, I believe we have missed the whole point of the article. Most people only looked at the editorials on the article and not the original a...

Test Your Knowledge Issue 368

Abbott announced last week that it received European CE Mark approval for the FreeStyle Navigator(R) Continuous Glucose Monitoring System for people with diabetes. U.S. Approval should also happen soon.

The U.S. FDA last week approved the 7-day use sensor to go with their CGMS system, a device that measures glucose levels continuously for up to seven days in people with diabetes. 

Exenatide can be an alternative to insulin glargine as an add-on treatment in patients with type 2 diabetes who are already receiving single-agent oral therapy, as presented as new research.

Doctors need to use these systems as part of overall improvement plan, but the electronic medical record systems are no guarantee that diabetes patients will get better care, a new study finds.

High glycosylated hemoglobin levels in women with gestational diabetes are associated with the development of diabetes in the future, new research indicates.

In a discovery that may explain the successes of the Atkins diet, investigators have found that a single hormone may switch on the use of stored fat for fuel when all else fails.

Researchers have discovered a potential new target for treating type 2 diabetes, according to a new study that appeared online in Nature. The target is a protein, along with its molecular partner, that regulates fat metabolism.

Saliva may be a marker for both periodontal disease activity and hyperglycemia in uncontrolled type 2 diabetes, according to new research.

Type 2 diabetes has a negative effect on brain tissue volumes and regional cerebral perfusion in elderly patients, according to researchers

A new once-weekly formulation of exenatide improves glycemic control and fosters weight loss in patients with type 2 diabetes, according to a new report.

Positive results are dependent upon BMI at start of therapy

Study shows that insulin resistant can be an independent risk factor for cardiovascular disease.

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) approved JANUMET™, the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (also known as JANUVIA™), and metformin for the treatment of typ...

The FDA Commissioner Andrew C. von Eschenbach, M.D., told a congressional hearing that the FDA will beef up the cardiovascular warnings on the labels of both rosiglitazone (Avandia) and pioglitazone (Actos).

Findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), shows further proof the safety of Avandia.

To often our patients tell us they can't increase their physical activity because of the complications of their disease. Dr. Sheri Colberg, author of The 7 Step Diabetes Fitness Plan: Living Well and Being Fit with Diabetes, has the right things to do...